Feds endorse use of antialcoholism injection
SAMHSA, the Substance Abuse & Mental Health Services Administration, has recognized the use of naltrexone extended-release injectable suspension (Vivitrol, Cephalon/Alkermes) for the treatment of alcohol dependence as part of its Spring 2007 Substance Abuse Treatment Advisory.
SAMHSA, the Substance Abuse & Mental Health Services Administration, has recognized the use of naltrexone extended-release injectable suspension (Vivitrol, Cephalon/Alkermes) for the treatment of alcohol dependence as part of its Spring 2007 Substance Abuse Treatment Advisory. The new issue includes information for healthcare professionals regarding patient adherence, safety, and efficacy of the treatment. Vivitrol is a once-monthly, intramuscular injection indicated for patients who have abstained from alcohol consumption the week prior to treatment initiation. The new advisory, Naltrexone for Extended-Release Injectable Suspension Treatment of Alcohol Dependence, is available on-line at
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
